{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CCRN",
  "name": "Cross Country Healthcare, Inc.",
  "url": "https://orbyd.app/dossiers/CCRN/",
  "json_url": "https://orbyd.app/dossiers/CCRN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Cash merger-arb in its final mechanical innings: shareholders adopted the $13.25 Knox Lane take-private on 2026-07-16 (~72% of shares for) and HSR is cleared, leaving only customary closing before delisting. Pennies of upside vs a residual deal-break gap toward ~$9–10 — no momentum leg left to trade.",
  "invalidation_trigger": "A daily close below $12.50 breaks the ~$13.2x arb band and signals deal doubt; a merger-termination 8-K or a re-rate toward standalone ~$9–10 confirms the break. Inverse: the deal closes near $13.25 and the stock delists, ending the situation with no residual upside.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "HSR cleared 2026-06-22 for BOTH the merger and the locums-business sale to All Star Healthcare Solutions — no second request; the antitrust failure mode that killed the prior deal is retired.",
    "Knox Lane buyout: $13.25/share cash, ~$437M, ~17x EBITDA, announced 2026-05-06, entity KL Criss Cross Intermediate, LLC; guided Q3-2026 close; 31% premium to 2026-05-06 close, ~45% to 90-day VWAP.",
    "Deal-break downside ~$9–10 (2026-05-02 pre-announcement reference ~$10.11–$10.23) vs pennies of upside to $13.25 — fails >3:1; dormant/avoid for a momentum book, no fundamental floor if it breaks.",
    "Outside date 2026-10-06; two automatic 3-month extensions (2027-01-06 / 2027-04-06) apply ONLY if HSR were outstanding — moot now, mechanism effectively dead. Parent regulatory termination fee $14,213,075.",
    "NOT managed care — CCRN is healthcare / travel-nurse + locums STAFFING; any legacy 'health-managed-care' theme tag is mislabeled.",
    "Prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024) terminated 2025-12-03 on stalled horizontal-overlap HSR review during a 43-day govt shutdown; Aya paid $20M break fee.",
    "Merger-objection litigation live: two stockholder suits + demand letters; company denies, filed supplemental DEFA14A disclosures; Wohl & Fruchter renewed investigation 2026-07-15.",
    "Q1-2026 (reported 2026-05-07): revenue $241.1M (-17.8% YoY vs $293.4M), net loss $4.3M / -$0.14 LPS; standalone business contracting into the buyout."
  ],
  "body_markdown": "## Current Thesis\nCCRN is a cash merger-arb whose optionality is nearly spent, and it sits in the dormant/avoid bucket for a momentum book. On 2026-05-06 Knox Lane agreed to take the company private at **$13.25/share cash, ~$437M**, through KL Criss Cross Intermediate, LLC — a 31% premium to the prior close and ~45% to the 90-day VWAP. The two gates that mattered are now behind it: **HSR waiting periods for both the merger and the carve-out of the locums business to All Star Healthcare Solutions expired 2026-06-22** with no second request, and **shareholders adopted the merger on 2026-07-16 (23,356,105 for, 12,309 against, 10,439 abstentions — ~72% of shares outstanding)**. What remains is customary closing mechanics, after which the stock delists from Nasdaq and deregisters. The tape trades like short-dated paper pinned to par: pennies of upside to $13.25, no pullback to buy, no breakout to chase.\n\n## Bull Case\n- **The binary events are resolved in favor of completion.** HSR cleared cleanly on 2026-06-22 for both the merger and the locums sale; the shareholder vote carried on 2026-07-16 with ~72% of outstanding shares in favor and negligible opposition. The regulatory theory that killed the prior deal is absent here — Knox Lane is a financial sponsor with no staffing overlap.\n- **This is a materially cleaner setup than the last attempt.** The prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024) was terminated 2025-12-03 when a stalled horizontal-overlap review during a 43-day government shutdown ran the clock out; Aya paid a $20M break fee. A PE buyer with no antitrust overlap removes that failure mode.\n- **Spread implies near-certain close.** With the reference price pinned in the low-$13.2x range against $13.25 cash and only administrative steps left, the market is pricing completion at very high odds and a close guided to Q3-2026 — plausibly within days-to-weeks of the vote.\n- **The sponsor is bonded.** A **$14,213,075 Parent regulatory termination fee** is payable if antitrust conditions fail or Knox Lane breaches its regulatory obligations, and the locums sale to All Star was sequenced through the same HSR window rather than left as a trailing condition.\n\n## Bear Case\n- **Payoff geometry is the wrong shape for a trend book.** Best case is a few cents to $13.25 and then delisting; a break re-rates the stock toward standalone ~$9–10 (the 2026-05-02 pre-announcement reference was ~$10.11–$10.23), a ~25%+ air-pocket. Risking ~25% to capture pennies fails the >3:1 bar by definition.\n- **The underlying business is contracting into the close.** Q1-2026 (reported 2026-05-07) revenue **$241.1M, -17.8% YoY** (vs $293.4M); net loss **$4.3M / -$0.14 LPS** (vs -$0.02 a year prior), with Nurse & Allied (~$201.4M) and Physician (~$39.6M) both showing lower volumes and margin compression. If the deal broke, there is no fundamental floor and the re-rate could undershoot $10.\n- **Objection litigation remains live.** Two stockholder suits plus demand letters allege proxy-disclosure deficiencies; the company denies them and filed supplemental disclosures (DEFA14A). These rarely block a close but generate headline noise, and a plaintiff firm (Wohl & Fruchter) publicly renewed its investigation on 2026-07-15.\n- **Second take-private attempt in ~18 months.** Management already had one buyout collapse on regulatory timing, so any process hiccup gets outsized attention even with Knox Lane's cleaner profile.\n\n## Setup & Price Structure\nPrice is pinned in the low-$13.2x zone, a few cents below the $13.25 cash terms and inside a 52-week range whose $14.88 high was set on takeover optimism against a $7.43 low. The chart carries no trend information now — realized volatility has collapsed to near-zero as the stock converges to deal value, and volume is arb-desk mechanical rather than directional. There is no moving-average structure to trade: the name is a bond-like convergence trade, not a momentum vehicle. The only structural break worth watching is a decisive move below the arb band, which would signal the market re-pricing completion odds. Absent that, the stock drifts to $13.25 and delists.\n\n## Catalyst Calendar (next 30 days)\n\n- **Outside date 2026-10-06 (backstop).** Two automatic 3-month extensions (to 2027-01-06 / 2027-04-06) exist only if HSR clearance were still outstanding — moot now that HSR is done, so the extension mechanism is effectively dead.\n- **No standalone Q2-2026 print expected to matter** — a normal early-August release date is superseded by the pending close; earnings are not a driver for a deal-pinned name.\n\n## Elapsed catalysts\n\n- **Merger closing / effective date — imminent, undated (guided Q3-2026).** With HSR cleared (2026-06-22) and the vote carried (2026-07-16), close typically follows within days-to-weeks; the stock delists from Nasdaq and deregisters under the Exchange Act on completion. *(passed 24d ago)*\n- **Merger-objection litigation headlines — ongoing.** Wohl & Fruchter renewed its investigation 2026-07-15; supplemental proxy disclosures already filed. Watch for any injunction attempt, which would be the only realistic procedural delay. *(passed 25d ago)*\n\n## What Would Change Our Mind\nThe situation only becomes tradable for a momentum mandate on a deal break followed by a genuine staffing-cycle re-acceleration — two independent events, neither in evidence. Concretely: a **merger-termination 8-K**, a **daily close below $12.50** that breaks the arb band, or a standalone re-rate toward ~$9–10 would flip the read from \"avoid — spent optionality\" to \"watch a broken deal for a fresh setup.\" Bill-rate stabilization and sequential revenue growth at AMN Healthcare and the broader travel-nurse group would be the fundamental tell that the staffing cycle had turned. Until one of those prints, there is no narrative leg to buy — the trade closed itself on 2026-07-16.\n\n## Correlation Notes\nUntil close, CCRN is idiosyncratic and deal-pinned — near-zero beta to SPY, healthcare, or its staffing peers, since price is a function of completion probability and time-to-close rather than sector flows. The relevant comps are the travel-nurse and locums staffing group — AMN Healthcare (AMN) and privately held CHG — where bill rates continue normalizing off COVID-era peaks and volumes remain soft; that depressed backdrop is exactly why a deal-break scenario would re-correlate CCRN sharply back down into the group. The only cross-asset sensitivity worth flagging is regulatory/antitrust regime tone, which is the variable that broke the Aya deal; with HSR already cleared for both the merger and the locums sale, that channel is closed for this transaction.",
  "first_seen": "2026-05-19",
  "last_analyzed": "2026-07-26T12:05:09+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}